Value Add VC tracks 1 company Vida Ventures has invested in and 1 venture round it took part in (0 as lead).
Vida Ventures key facts (as of )
| Fact | Value | Source |
|---|---|---|
| Type | Venture capital firm | Value Add VC classification |
| Funds tracked | 1 | Funds table on this page (each fund cites its source) |
| Venture rounds tracked | 1 (led 0, joined 1) 1 in the last 12 months | Recent deals table on this page (each round cites its source) |
| Portfolio companies tracked | 1 | Portfolio list on this page |
Recent deals we track
1Track record: led 0 and participated in 1 of 1 tracked venture round · 1 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Souffle Therapeutics | Series B | Participated | $135M | — | Fidelity InvestmentsunverifiedARCH Venture PartnersunverifiedBessemer Venture PartnersunverifiedJanus Henderson InvestorsunverifiedLeaps by BayerunverifiedPolaris PartnersunverifiedTemasekunverifiedVida VenturesunverifiedJuvia GroupTCG Crossover ManagementBB BiotechBalyasny Asset Management+5 more | FinancialContent |
Is this your firm? Get featured or correct your listing →
We track Vida Ventures but have little verified detail yet.
Recent changes
- Oct 13, 2026Oct 13, 2026Invested in Souffle Therapeutics (Series B, $135M) FinancialContent
- Sep 22, 2026Sep 22, 2026New fund: Vida Ventures Fund IV (target $500M) SEC EDGAR Form D
Funds
1| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| Vida Ventures Fund IV | 2026 | target $500M | Flagship | As of Sep 22, 2026SEC EDGAR Form D |
Portfolio
1 totalCo-Investors
5Latest Pulse
- Oct 13, 2026Souffle Therapeutics Raises $135M For RNA TherapiesSouffle Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group on Oct. 13 to push its RNA-delivery platform's first three programs toward the clinic.→
- Jun 10, 2026SonoThera Raises $125M for Ultrasound Gene TherapySonoThera closed an oversubscribed $125 million Series B led by Vida Ventures to push its ultrasound-delivered, nonviral genetic medicine platform toward its first clinical trial in Duchenne muscular dystrophy in 2027.→
Vida Ventures FAQ
What stage does Vida Ventures invest at?
In the rounds Value Add VC tracks, Vida Ventures' deals were most often Series B (1).
What companies has Vida Ventures backed?
Companies Value Add VC tracks as Vida Ventures investments include Souffle Therapeutics.
Who does Vida Ventures co-invest with most?
In the rounds Value Add tracks, Vida Ventures most often invests alongside ARCH Venture Partners (1 shared deal), Bessemer Venture Partners (1 shared deal), Fidelity Investments (1 shared deal), Janus Henderson Investors (1 shared deal), Temasek (1 shared deal).
Sources & methodologyshow
- SEC EDGAR Form Dprimary source1 fact
- FinancialContentresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.